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Abstract: Treatment of the neovascular form of age-related macular degeneration (AMD) 
has been revolutionized by the introduction of such agents as ranibizumab, bevacizumab, and 
aflibercept. As a result, the incidence of legal blindness occurring secondary to AMD has fallen 
dramatically in recent years in many countries. While these agents have undoubtedly been suc-
cessful in reducing visual impairment and blindness, patients with neovascular AMD typically 
lose some vision over time, and often lose the ability to read, drive, or perform other important 
activities of daily living. Efforts are therefore under way to develop strategies that allow for 
earlier detection and treatment of this disease. In this review, we begin by providing an overview 
of the rationale for, and the benefits of, early detection and treatment of neovascular AMD. To 
achieve this, we begin by providing an overview of the pathophysiology and natural history 
of choroidal neovascularization, before reviewing the evidence from both clinical trials and 
“real-world” outcome studies. We continue by highlighting an area that is often overlooked: 
the importance of patient education and awareness for early AMD detection. We conclude the 
review by reviewing an array of both established and emerging technologies for early detection 
of choroidal neovascularization, ranging from Amsler chart testing, to hyperacuity testing, to 
advanced imaging techniques, such as optical coherence tomography.
Keywords: Amsler, detection, choroidal neovascularization, hyperacuity, optical coherence 
tomography
Introduction
The treatment of age-related macular degeneration (AMD) has been revolutionized by 
the introduction of successful pharmacotherapies, such as ranibizumab, bevacizumab, 
and aflibercept, for the neovascular form of the disease.1 Data from a number of coun-
tries illustrate this point. In Denmark, the incidence of legal blindness from AMD has 
fallen by half between 2000 and 2010, with the bulk of the reduction occurring after the 
introduction of ranibizumab and bevacizumab.2 In Israel, a similar reduction in legal 
blindness has been reported since the introduction of these therapies.3 In Australia, it 
is estimated that monthly injections with ranibizumab for patients newly diagnosed 
with neovascular AMD would lead to a 72% reduction in incident blindness over a 
2-year period.4 Finally, in the US it is estimated that the use of monthly ranibizumab 
injections would reduce the number of cases of incident blindness from 16,268 to 
only 4,484 individuals over a 2-year follow-up.5 While these drugs are undoubtedly 
successful in reducing visual impairment and blindness, patients with neovascular 
AMD typically lose some vision over time, and often lose the ability to read, drive, 
or perform other important activities of daily living.6 Efforts are under way to develop 
new pharmacotherapies and other novel approaches to treatment.7 However, developing 
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strategies to allow for earlier detection and treatment of this 
disease may be equally if not more effective.
In this review, we begin by providing an overview of the 
rationale for and the benefits of early detection and treatment 
of neovascular AMD (no effective treatment yet exists for 
the nonneovascular form of the disease). To achieve this, 
we begin by providing an overview of the pathophysiology 
and natural history of choroidal neovascularization (CNV), 
before reviewing the evidence from both clinical trials and 
“real-world” outcome studies. We continue by highlighting 
an area that is often overlooked: the importance of patient 
education and awareness for early AMD detection. We con-
clude the review by reviewing an array of both established 
and emerging technologies for early detection of CNV, 
ranging from Amsler chart testing, to hyperacuity testing, 
to advanced imaging techniques, such as optical coherence 
tomography (OCT) (Table 1).
Benefits of early detection and 
treatment
Histopathology of choroidal 
neovascularization
In AMD, the development and progression of CNV is 
responsible for more than 80% of severe visual loss.8 In 
this process, new blood vessels sprout from the choroidal 
circulation, penetrate the overlying Bruch’s membrane, and 
grow within the subretinal pigment epithelium space (type 1 
CNV) or the subretinal space (type 2 CNV), or a combina-
tion of both.9 In some cases, intraretinal neovascularization 
may also occur, leading to formation of a retinal–choroidal 
anastomosis; such lesions are typically referred to as retinal 
angiomatous proliferation or type 3 neovascularization.10
Development of type 1 CNV is thought to begin at 
multiple sites, with the penetration of Bruch’s membrane 
by new vessels from the choroid.9 These vessel tufts expand 
laterally in a horizontal fashion, utilizing the natural cleav-
age plane between the retinal pigment epithelium (RPE) 
and Bruch’s membrane. This growth pattern is thought to 
correspond to the appearance of “occult” leakage on fundus 
fluorescein angiography (FA; the neovascular membrane 
is covered by the RPE, so its leakage is typically only seen 
in the late frames of the angiogram).11,12 Patients are often 
relatively asymptomatic, presumably because the overlying 
neurosensory retina is largely intact.
In type 2 CNV, penetration of Bruch’s membrane – and 
the RPE – occurs at a single or few ingrowth sites, with 
subsequent neovascular proliferation in the subretinal space.9 
As this process occurs above the RPE, the outer blood–
retinal barrier does not protect the retina, and leakage from 
new vessels results in relatively acute visual symptoms. On 
angiography, this growth pattern is easily seen as a “classic” 
pattern of fluorescein leakage (as it lies predominantly above 
Table 1 Techniques and diagnostic tools for the early detection and diagnosis of neovascular age-related macular degeneration
Test Description Comments
Amsler chart (classical) evaluates the 20° of visual field centered on fixation.31
The complete set of Amsler charts consists of seven  
plates, each consisting of a 10 cm square with a  
central spot for fixation.
each chart is held at approximately 30 cm,  
and the patient is asked to fixate on the central  
dot, reporting any distortion, blurred areas,  
or blank spots anywhere on the grid.
Although widely used with patients with AMD  
since at least the 1960s, sensitivity and specificity  
for the detection of AMD is low.31
This poor performance is related to such factors  
as cortical completion (“filling in”) and crowding  
phenomena, as well as poor patient compliance.
Amsler chart  
(automated, threshold)
Standard Amsler chart testing is a suprathreshold  
stimulus, and thus relative scotomas may go  
undetected. In “threshold” Amsler chart testing,  
the subject is asked to view a white-on-black 
version of the chart through cross-polarizing filters.42
An automated, computerized version of the threshold  
Amsler test has also been developed; patients are  
instructed to map any observed distortion of scotomas  
using a standard Amsler grid displayed on a touch- 
screen computer display at different contrast levels.  
A three-dimensional depiction of the visual field  
defect is then produced.44
High reproducibility for detection of central  
visual field defects on repeat testing in patients  
with AMD.45
Quantitative analyses may also allow differentiation 
between neovascular and nonneovascular forms  
of AMD.50
(Continued)
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Table 1 (Continued)
Test Description Comments
Preferential hyperacuity  
perimetry (PHP)
The patient is presented with a pattern of dotted  
lines projected for 160 ms to the central 14°  
of their visual field. Any geometric shift in retinal morphology 
occurring in the stimulated area will  
lead to a hyperacuity defect, and thus the perception  
of distortion.37
Each dotted line also contains an artificial distortion  
of varying magnitude. This serves as a competitive  
stimulus to any pathologic distortion, if present.  
The point at which a test subject becomes aware  
of a pathologic distortion over an artificial  
distortion provides a measure of its magnitude.
initial studies demonstrated that PHP can detect  
recent-onset choroidal neovascularization  
with high sensitivity (82%), and can differentiate  
these patients from those with intermediate  
AMD only with high specificity (88%).54
The ForeseeHome device was evaluated in the  
HOMe study, a Phase iii randomized clinical trial.
This study provided the first definitive evidence  
of efficacy for a device allowing early detection  
and treatment of patients with neovascular AMD.57
Shape-discrimination  
hyperacuity (SDH)
An alternative form of hyperacuity measurement  
involves discrimination of shapes (eg, a perfect circle  
compared to one that has a distorted contour).60
Successful completion of such tests requires global  
shape-detection mechanisms, something that is impaired  
in patients with AMD but not in age-matched controls.61
A handheld SDH test (MyvisionTrack) has recently 
been implemented for use with smartphones.63
Health Management Tool, a remote monitoring  
system that utilizes the MyvisionTrack app, has  
recently been tested in a pilot clinical trial, but  
the results are not yet publicly available.
Macular mapping test  
(MMT)
The MMT is a software program used in conjunction  
with a desktop computer.66
Letters are briefly displayed in the central visual field  
(8° radius) on the computer display. A constant  
background pattern in a wagon-wheel shape aids  
the test subject in maintaining fixation on the center  
of the display area.
Designed primarily for quick assessment of residual 
vision in patients with maculopathies.
Considerable test–retest variability may  
be a limitation.67
entoptic perimetry when patients with an acquired scotoma stare at  
images of random visual noise (eg, video static),  
they often perceive an inhomogeneous region  
corresponding to their scotoma.68
Once the scotoma is perceived in this manner,  
it is often possible to map it, a procedure referred  
to as entoptic perimetry.
Although not very effective in eliciting scotomas  
from postchiasmal lesions or from the physiological 
blind spot, variations of this technique have been  
successfully used to screen for visual field defects  
caused by prechiasmal ocular diseases, including  
AMD.70
Optical coherence  
tomography (OCT)
OCT is an imaging modality that provides cross-sectional  
imaging of the retina in a noninvasive manner.71
Due to its extremely high resolution, OCT may allow  
early detection of neovascular AMD disease features  
(eg, subretinal fluid) before patients become  
symptomatic.73
initial studies with time-domain technology suggest  
that OCT has a greater specificity than PHP  
or Amsler chart testing for the detection of new- 
onset neovascular AMD. However, using this older 
technology, OCT was found to be less sensitive  
than conventional fundus fluorescein angiography.74
Newer “swept source” laser-light sources may  
allow OCT systems to become handheld  
and portable. Binocular OCT designs may  
allow comprehensive eye examination  
to be performed by patients themselves without  
the need for skilled personnel to acquire images.72
Commercially available OCT devices are now  
capable of performing retinal and choroidal  
angiography in a noninvasive manner.72
Abbreviation: AMD, age-related macular degeneration.
the RPE, the fine vessels of the neovascular membrane may 
be clearly seen in the early angiographic phases).12
In both type 1 and type 2 CNV, the growing neovascular 
membrane is initially capillary-like.9 These fenestrated and 
friable vessels leak serous fluid, lipid, and blood into the 
retina and surrounding potential spaces. Vascular invasion 
is also accompanied by infiltration of macrophages and 
other inflammatory cells, which produce matrix metal-
loproteinases, and thus allow the growing membrane to 
digest through tissue planes.13 Macrophages also produce 
a range of other mediators, including proinflammatory and 
proangiogenic factors. At some point, the balance of growth 
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factors and inflammatory mediators shifts toward an anti-
angiogenic, antiproteolytic, and antimigratory state, and so 
the invading vessels becoming arterial or venular, and the 
CNV lesion as a whole becoming fibrosed.9 This process is 
known as disciform scar formation, and is associated with 
irreversible visual loss.
Natural history of choroidal 
neovascularization
Prior to the introduction of effective therapies for neovascular 
AMD (eg, anti-VEGF agents), randomized clinical trials 
for this condition typically included control arms where no 
treatment was given. The results from these studies therefore 
provide a unique opportunity to investigate the natural history 
of CNV growth (typically measured as area and diameter 
of the CNV lesion on FA imaging) and its effects on visual 
acuity in patients with AMD.
In 2008, Wong et al performed a systematic review and 
meta-analysis of patients with neovascular AMD enrolled 
in untreated control arms of clinical trials between 1980 
and 2005.14 Their work demonstrated a consistent, steady 
deterioration in vision in untreated patients over the first few 
years following CNV onset. On average, these patients expe-
rienced one line of visual acuity loss at 3 months, 2.7 lines 
at 12 months, and four lines lost by 24 months. By 3 years, 
41.9% of eyes had experienced severe visual loss (more 
than six lines lost), and 75% of patients had a visual acuity 
of 20/200 or worse at this time point (ie, legal blindness). Of 
note, their review also demonstrated the development of CNV 
in the fellow eye in 12.2% of patients by 12 months, and in 
26.8% of patients by 4 years. Another Medicare-based US 
study reported cumulative rates of progression to neovascular 
AMD were 2.6% in year 1, which increased to 20.4% over 
a 10-year period.15 Of additional note, patients with retinal 
angiomatous proliferation lesions have a very high risk of 
second-eye involvement (36% within 3 years).16
In 2013, Liu et al conducted a retrospective meta-analysis 
of data from five seminal AMD clinical trials (the TAP and 
VIP trials of photodynamic therapy [PDT], the VISION trial 
of pegaptanib, and the MARINA and PIER trials evaluating 
ranibizumab).17 They used untreated, control-eye data from 
these trials to report progression of CNV lesion size, and thus 
to estimate the growth rate of untreated lesions. Their results 
suggest that the main determinant of lesion-size progression 
is the duration of neovascular disease, with smaller lesions 
enlarging more rapidly than larger lesions. They estimate that 
for smaller lesions, the edge of the neovascular membrane 
advances at 26.0 µm per day. As a result, their data predict 
that by 8 days after initial formation, CNV lesions can 
transform from being undetectable to having a diameter of 
416 µm. For longstanding lesions, they predict that the CNV 
edge will advance more slowly, at 7.3 µm per day. Perhaps 
most interestingly, from analysis of initial CNV lesion size, 
they estimate that even the earliest enrolled patients in these 
studies had had their CNV for 7.7 months prior to entry in 
the clinical trial.
Clinical trial outcomes
With the introduction of effective pharmacotherapies for 
neovascular AMD, subgroup analyses from clinical trials 
have provided further evidence for the benefits of early 
treatment.
In the TAP and VIP studies of PDT with verteporfin, the 
greatest benefit was seen in patients with smaller lesions at base-
line (fewer than four Macular Photocoagulation Study [MPS] 
disk areas; each MPS disk area 2.5 mm2).18 For all verteporfin-
treated lesions, irrespective of angiographic subtype, the amount 
of visual acuity loss appeared to be related to lesion size. For 
example, in “occult with no classic” lesions, the mean visual 
acuity loss for the smallest lesions was nearly four times less 
than for the largest lesions, while for lesions with “predomi-
nantly classic” or “minimally classic” composition, the mean 
visual acuity loss was nearly half that in the largest lesions.
In the MARINA study evaluating the use of ranibi-
zumab in the treatment of minimally classic and occult 
CNV lesions, subgroup analysis demonstrated that larger 
lesion size at baseline was associated with a greater loss of 
letters in the sham-treatment group and less gain of letters 
in the two ranibizumab-treatment arms.19 Similarly, in the 
ANCHOR study evaluating the use of ranibizumab for the 
treatment of predominantly classic CNV, smaller baseline 
CNV lesion size was associated with greater gain of letters 
in those receiving ranibizumab and less loss of letters in 
those receiving PDT.20
Finally, in the CATT study comparing the use of 
ranibizumab with bevacizumab, the mean baseline visual 
acuity score was 61 letters (Snellen equivalent 20/63), and 
the median total area of CNV lesion was 4.3 mm2 (range 
0.05–56.9 mm2). A larger area of CNV at baseline was 
associated with worse visual acuity at 1 year, less gain in 
visual acuity at 1 year, and a lower proportion gaining three 
or more lines.21
Real-world outcomes
The outcomes of treatment for neovascular AMD in the real 
world may not always reflect those obtained in the context 
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of randomized clinical trials. Traditionally, retrospective 
audits have been used to address this issue, although these 
typically involve retrospective collection of incomplete 
data from small numbers of patients in single centers, with 
considerable risk of publication bias in the event of low 
success rates. The increasing use of electronic medical 
records (EMRs) with mandatory core data sets is beginning 
to address this issue. Such systems allow data with a pre-
defined structure to be collected as a by-product of routine 
clinical care, and allow sample sizes similar to those seen in 
the general population. As such, the use of EMRs has greatly 
improved assessment of real-world outcomes, and further 
emphasized the benefits of early detection and treatment of 
patients with neovascular AMD. Use of EMRs also allows the 
inclusion of second-treated eyes of patients: something that 
is specifically excluded from most clinical trials, and likely 
to be of great significance for patients, as visual outcomes 
in a better-seeing eye are likely to have the greatest impact 
on quality of life.
The UK Neovascular AMD Database Study evalu-
ated real-world outcomes in second-treated eyes receiving 
anti-VEGF therapy.22,23 Regular follow-up of patients after 
initiating treatment in the first eye gives an opportunity to 
screen a high-risk population of fellow eyes using visual acu-
ity measurements, OCT scanning, and fundus examination. 
The results of this study provide strong evidence that such 
screening leads to early detection of fellow-eye disease. Spe-
cifically, the mean baseline visual acuity of second-treated 
eyes was considerably better than that in first-treated eyes, 
suggesting earlier detection. The results from this study also 
suggest that earlier treatment leads to better outcomes, with 
better maintenance of vision in the second-treated eye over 
several years of follow-up.
Delays in presentation and treatment
Once CNV formation occurs, the evidence from clinical 
trials is clear: smaller lesions tend to respond better to treat-
ment. A number of small studies have attempted to directly 
assess the effects of treatment delay, either from delays in 
patient presentation or from delays between diagnosis and 
the initiation of treatment.
In 2005, Oliver-Fernandez et al, working in the Canadian 
health care system, found a median time between initial 
diagnosis and treatment of 28 days resulted in a degree of 
visual loss in 44% of subjects.24 In this pilot study of 38 con-
secutive patients newly diagnosed with neovascular AMD, 
15% of subjects lost three or more lines of distance visual 
acuity, and the mean loss of visual acuity in the affected 
eye was 0.24 logarithm of the minimum angle of resolution 
units. Of note however, this study was performed prior to the 
introduction of ranibizumab or bevacizumab for treatment 
of this condition.
The effect of symptom duration has also been assessed. 
In 2012, Rauch et al performed a retrospective evaluation of 
patients receiving ranibizumab for neovascular AMD.25 They 
divided a cohort of 45 subjects into three groups depending 
on their duration of visual symptoms: 1 month, 1–6 months, 
and 6 months. They found a mean time between initial 
symptoms and treatment of 59±62 days, and that shorter 
disease duration, as estimated by the prevalence of symptoms, 
was correlated with a better visual outcome after treatment. 
Similarly, in 2014 Canan et al retrospectively reviewed 104 
eyes from patients undergoing intravitreal ranibizumab ther-
apy for neovascular AMD. Again, they divided their patient 
cohort into groups according to their symptom duration 
(1 month and 1–3 months), and demonstrated better visual 
outcomes in patients with shorter duration of symptoms.26
Patient education and awareness
Increasing awareness and knowledge of AMD in the general 
population may be an important first step toward aiding early 
detection and treatment. In the US, Australia, and Canada, 
between 20% and 30% of respondents to a recent survey indi-
cated that they were “very familiar” or “somewhat familiar” 
with AMD.27,28 However, much lower levels of awareness 
have been reported in Asian regions, such as Japan and Hong 
Kong,29 and survey data are not available for many countries. 
With better education and awareness, older people may be 
more likely to have their eyesight tested regularly or partici-
pate in screening programs for ocular disease. Better disease 
understanding may allow at-risk populations to modify their 
lifestyles to reduce the impact of such factors as smoking or 
diet, or to pursue more frequent monitoring for the disease. 
In fact, the Scientific Advisory Panel of the AMD Alliance 
International recommends that people 55 years of age or older 
should have regular dilated fundus examinations performed 
by a qualified eye health professional every 2 years as part of 
an overall health package for vision. Elderly populations also 
need to be aware of the symptoms of AMD, so that prompt 
eye care can be sought should they occur.
In many countries, efforts to promote education and 
public awareness of AMD in the general population are 
under way. In particular, medical charity groups (eg, the 
Macular Society in the UK) provide patient support and 
self-help groups, as well as arranging public forums for 
education of the general public. Eye hospitals and clinics 
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also have a role to play, particularly when they serve large 
populations or regions of a country. For example, in the 
UK, Moorfields Eye Hospital in London organizes regular 
patient information and support days for specific diseases, 
such as AMD. The AMD Awareness Week, held in con-
junction with the global initiative by AMD Alliance Inter-
national, seeks to generate awareness and understanding 
of the disease, in addition to promoting the importance of 
education, early detection, and knowledge of treatment and 
rehabilitation options.
Health campaigns have been shown to be useful in 
improving the utilization of eye care services. The benefits 
of such campaigns extend beyond AMD in isolation: eye-
screening examinations present an opportunity not only to 
detect AMD but also other prevalent age-related eye diseases, 
such as cataract, glaucoma, and diabetic retinopathy. In 
Australia, the Vision Initiative was a public health campaign 
that promoted early detection of the main causes of vision loss 
through regular eye examinations.30 In this initiative, target 
groups included those over the age of 50 years with diabetes, 
those who had noted changes in their vision, or those with a 
family history of glaucoma or AMD. This campaign was car-
ried out in 2005, and involved a range of promotions through 
metropolitan and regional television, radio, and newspapers. 
Following the campaign, an improvement in the utilization 
of eye care services was noted, particularly by subjects with 
diabetes mellitus.
Amsler chart monitoring
Basic principles and technique
Since the 1960s, it has been widely recommended that 
patients at risk of CNV formation should be given an Amsler 
chart to detect early changes in their visual function and hence 
facilitate early detection and treatment.31 Amsler charts (or 
“grids”) were first described in 1947 by Marc Amsler, a Swiss 
ophthalmologist, and likely inspired by the small cards with 
grid patterns used by Landholt to place in the center of his 
perimeter when testing the macula.32,33
Amsler charts evaluate the 20° of the visual field cen-
tered on fixation (ie, they subtend an angle of 20° when 
viewed from the recommended distance of 30 cm).31 The 
complete set of Amsler charts consists of seven plates, 
each consisting of a 10 cm square with a central spot for 
fixation. Chart 1 comprises a high-contrast white grid on 
a black background. The outer grid encloses 400 smaller 
5 mm squares. When the central spot is viewed at a distance 
of about 30 cm, each small square subtends an angle of 1°. 
Chart 2 is similar to chart 1, but has diagonal lines that 
aid fixation on the central spot in patients with a central 
scotoma. Chart 3 is similar to chart 1, but has red squares 
instead of white. This red-on-black design aims to stimu-
late long-wavelength cones in the fovea, and thereby aid 
detection of red desaturation in toxic maculopathies, optic 
neuropathies, and chiasmal lesions. Chart 4 is a version 
with dots instead of lines, formulated to aid differentiation 
between scotomas and metamorphopsia. Chart 5 consists of 
horizontal lines only, and is particularly aimed at assessment 
of metamorphopsia in patients with reading difficulties. 
Chart 6 is similar to chart 5, but has a white background 
and has more closely spaced central lines, enabling more 
detailed evaluation. Chart 7 includes a fine central grid, 
with each square subtending an angle of 0.5°, theoretically 
allowing for greater sensitivity.
Amsler chart testing is performed with near-vision cor-
rection, if required, and with one eye covered.31 The chart is 
held at approximately 30 cm, and the patient is asked to fixate 
on the central dot, reporting any distortion, blurred areas, 
or blank spots anywhere on the grid. Patients with macular 
disease often report that portions of the lines are “wavy”, 
while those with optic neuropathies often note the absence 
of lines. The subject is also asked if all four corners and all 
four sides of the square are visible. Finally, the subject may 
be asked to trace out any detected positive or negative sco-
tomas on a paper version of the chart. Patients are typically 
advised to perform this testing at least once per week, and 
preferably more frequently.
While the classic version of the Amsler chart consists of 
white lines on a black background, a black-on-white version 
of the chart is used far more frequently by patients.31 This 
distinction is likely to have arisen due to a greater ease of 
printing or photocopying, and such charts are widely avail-
able through macular disease charities and pharmaceutical 
companies. Despite this, however, a recent comparison of 
these two formats found that distortion and scotomas were 
less obvious on the modified version of the chart that is in 
widespread use.34
An alternative and perhaps more pragmatic approach 
is so-called Environmental Amsler testing. In this method, 
patients are advised to perform vigilant observation of 
objects in their familiar environment – including edges of 
door frames, bathroom tiles, television screens, photo frames, 
etc – for distortion, and then to seek medical attention as 
appropriate. Using this approach, patients receiving anti-
VEGF therapy for neovascular AMD have recently been 
shown to be capable of predicting disease reactivation, and 
thus the need for retreatment.35
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evidence of diagnostic accuracy 
and/or screening benefit
Relatively limited evidence exists to judge the effectiveness of 
Amsler charts as a diagnostic test, and the evidence that does 
exist suggests that their diagnostic accuracy is limited.
In 1993, Schuchard performed Amsler chart testing using 
the TA-300 system (Stereo Optical, USA), and compared it to 
a reference standard of fundus perimetry (the latter allowed 
precise determination of the existence, size, and retinal loca-
tion of macular scotomas).36 Fifty-five patients with vision 
loss in the macular region and ten healthy volunteers without 
visual loss were evaluated, with testing performed under both 
standard and “threshold” lighting conditions (see later for a 
description of threshold testing). In this study, nearly half of 
all scotomas were not detected using the Amsler chart. For 
scotomas of 6° or less in diameter (ie, fewer than six small 
squares on the Amsler chart), 77% of standard and 87% of 
threshold scotomas were not detected. Also of note, in the 
eyes with central scotomas involving the fovea, 66% used 
an eccentric preferred retinal locus for fixating the center of 
the grid. Therefore, Schuchard argued that Amsler testing has 
“poor validity” and “cannot be accurately interpreted for use 
in clinical diagnosis of retinal defects”. In a subsequent study 
in 2003, Lowenstein et al calculated a sensitivity of Amsler 
chart testing of only 9% for patients with AMD with “high-
risk characteristics” for CNV formation, 7% for AMD patients 
with geographic atrophy (GA), and 34% for AMD patients 
with CNV.37 In addition to this high rate of false negatives, 
they found that Amsler testing was 1 (defined as “any percep-
tion of distortion, scotoma, or blurring . . . on the Amsler grid”) 
in 2% of the healthy controls included in their study.
The use of Amsler charts for screening of patients with 
AMD has not been comprehensively assessed. In 1986, 
Fine et al performed a survey of presenting symptoms 
in 103 patients with recent vision loss from neovascular 
AMD.38 Of 49 patients in the cohort who said that they were 
performing Amsler chart testing on a regular basis, only five 
indicated that the Amsler chart abnormality was their first 
visual symptom. In 2004, Zaidi et al assessed whether the use 
of Amsler charts led to increased detection of CNV lesions 
amenable to focal laser photocoagulation (ie, of potentially 
earlier onset).39 They found no difference in suitability for 
laser therapy in patients who presented with symptoms on 
Amsler versus those who presented in another manner.
Reasons for poor  performance
Numerous reasons exist for the potentially poor performance 
of the Amsler chart. As demonstrated by Schuchard, patients 
with macular disease are unlikely to notice a macular visual 
field defect until it reaches a certain size.36 This finding 
may be explained by cortical completion (“filling in”), 
a well-established phenomenon whereby visual features are 
perceived in the absence of neural input on the basis of sur-
rounding features.31 This is most commonly demonstrated 
over the physiological blind spot, where even under mon-
ocular conditions, no scotoma is visible in the visual field. 
Filling in has also been well demonstrated to occur across 
pathological scotomas, and even in healthy subjects with 
simulated scotomas. Other reasons for poor performance may 
include an inability to maintain appropriate fixation while 
testing the peripheral visual field (eg, in patients with central 
scotoma), and the crowding effect caused by the presentation 
of multiple, peripheral grid lines. Finally, the Amsler chart 
is noninteractive, potentially leading to poor compliance for 
long-term monitoring in a home setting and the inability to 
assess examination quality or reliability.
Modified Amsler chart testing
In the 1980s, Yannuzzi suggested the introduction of a credit 
card-size Amsler chart for increased convenience of testing, 
although this chart was slightly less sensitive than the conven-
tional Amsler grid.40 Amsler charts have also been developed 
consisting of blue grids on a yellow background, with the 
idea that most retinal and macular lesions cause blue–yellow 
defects, whereas optic nerve, chiasmal, and postchiasmal 
disorders tend to cause red–green defects.41
Standard Amsler chart testing is a suprathreshold 
stimulus, and thus relative scotomas may go undetected. In 
“threshold” Amsler chart testing, the subject is asked to view 
a white-on-black version of the chart through cross-polarizing 
filters.42 This allows variation in the perceived luminance of 
the chart, and patients viewing the grid through these filters 
often notice shallow scotomas not detected during standard 
testing. This effect was initially reported in patients with 
diabetic retinopathy: in 26 patients, 22 had scotomas detected 
with the threshold Amsler chart, yet only four were detected 
using the conventional Amsler chart.43 Of note however, 
this study did not employ any form of fundus perimetry as a 
reference standard, so it is unknown whether these patients 
actually had scotomas. Moreover, Schuchard noted a less 
impressive performance when testing was performed under 
more stringent conditions.36
An automated, computerized version of the threshold 
Amsler test has also been developed.44 In this system, patients 
are instructed to map any observed distortion of scotomas 
using a standard Amsler grid displayed on a touch-screen 
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computer display. The subject uses their finger to outline 
the margins of the defect on the touch screen at each of 
five contrast levels (100%, 80%, 60%, 40%, and 20%). The 
results are then analyzed to produce a three-dimensional 
depiction of visual field defects that can be analyzed in terms 
of slope, location, shape, and depth. This form of testing 
has been employed in patients with AMD, diabetic macular 
edema, glaucoma, and toxic optic neuropathy, with a high 
reproducibility for detection of central visual field defects 
on repeat testing.45–48 In patients with AMD, these central 
defects have been shown to correspond to anatomical findings 
on FA imaging, and quantitative analyses have been shown 
to distinguish between the neovascular and nonneovascular 
forms of AMD.49,50
Smartphone visual acuity and Amsler 
chart testing
Visual acuity and Amsler chart testing are now possible using 
smartphone technology. An example of this is the Mobile 
Vision Assessment System (DigiSight Technologies, USA), 
which provides tools to support standardized and frequent 
vision testing. The system integrates a vision-assessment 
application named SightBook running on a mobile device 
(eg, iPhone, Apple, USA) with an Internet-based vision 
care network and website. Tests provided include Snellen 
visual acuity, Amsler chart testing, contrast sensitivity, 
color discrimination, and low-luminance acuity/contrast. 
The associated DigiSight Network is a web service that 
enables the results of these tests to be instantly and securely 
uploaded for assessment by the user’s designated ophthal-
mologist (in cases of acute, significant reductions in visual 
function, the ophthalmologist may be alerted urgently and 
automatically).
Preferential hyperacuity perimetry
Basic principles
When a straight dotted line is presented to a healthy retina, 
a collinear set of retinal receptive fields is stimulated, and 
the information is processed in the visual cortex, leading 
to the perception of a straight dotted line. When changes 
in retinal morphology occur (eg, with RPE elevation, as 
occurs in AMD), a different set of photoreceptors may be 
stimulated, leading to perception of sections of the dotted 
line at a different location in space. The perceived shift 
in object location is the anatomic correlate for the symp-
tom of metamorphopsia. This symptom can be assessed 
and recorded using preferential hyperacuity perimetry 
(PHP).37
Hyperacuity is the human ability to perceive minute 
differences in the relative spatial localization of two objects 
in space (ie, minute misalignments between the borders 
of objects; also termed “Vernier acuity”).51 Hyperacuity 
transcends by far the size limits detectable using standard 
visual acuity testing, with thresholds as low as 3–6 seconds 
of arc. Perhaps more importantly, hyperacuity thresholds 
do not seem to vary with increasing age, and are highly 
resistant to retinal image degradation as a result of ocular 
media opacity.52,53
In PHP, the patient is presented with a pattern of dotted 
lines projected for 160 ms to the central 14° of their visual 
field.37 Any geometric shift in retinal morphology, occur-
ring in the stimulated area, will lead to a hyperacuity defect 
and thus the perception of distortion. PHP devices use the 
phenomenon of “attention competition” to further provide 
for quantification of the magnitude of pathologic distor-
tion. Each dotted line presented by the system contains an 
artificial distortion of varying magnitude. This serves as a 
competitive stimulus to any pathologic distortion, if present. 
In general, the brain ignores smaller distortion when an area 
of larger distortion is present. Therefore, the point at which 
a test subject becomes aware of a pathologic distortion over 
an artificial distortion provides a measure of its magnitude. 
Based on multiple responses from the subject, a visual field 
map can then be constructed, analyzed, and compared to 
normative data, and the likelihood of CNV determined. 
The basic principles and methods used for this test are best 
understood by undergoing it: this can be done online at 
www.foreseehome.com.
Detection of age-related macular 
degeneration – early studies
The results of the earliest clinical study involving PHP were 
reported in 2003.37 This study utilized a standard desktop 
computer with mouse and keyboard and software termed 
Macular Computerized Psychophysical Test. This testing 
was compared to Amsler chart testing under supervised 
conditions in a doctor’s office. The results of this study 
suggested that PHP was more sensitive than the Amsler 
chart for each category of AMD: those with CNV, those 
with GA, and those with “high-risk characteristics” for 
CNV development. The results of this pilot study were 
confirmed in a subsequent multicenter international study, 
published in 2005.54 A significant rate of false positives was 
detected from healthy control subjects, however, leading 
to refinements in the underlying algorithm for subsequent 
studies.
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PHP was further developed to differentiate between 
patients at high risk for developing CNV (ie, those with 
intermediate AMD) and patients with recent-onset CNV, 
to evaluate the potential role for PHP in monitoring for 
CNV development.55 This study, involving multiple centers 
in the US, Europe, and Asia, demonstrated that PHP can 
detect recent-onset CNV with high sensitivity (82%), and 
can differentiate these patients from those with intermediate 
AMD only with high specificity (88%). In the same study, 
the diagnostic accuracy of color stereophotography was also 
evaluated (simulating clinical biomicroscopy), and found to 
be considerably less impressive than that of PHP. The device 
used in this study received US Food and Drug Administration 
(FDA) approval, and was originally marketed by Carl Zeiss 
Meditec as the Preview PHP, before becoming available from 
Notal Vision (Israel) as the Foresee PHP.
AReDS2 and the HOMe study
Notal Vision subsequently developed a PHP device for use 
by patients within their own homes: the ForeseeHome device. 
This device was then evaluated in a Phase III, unmasked, 
randomized clinical trial: the HOME (Home Monitoring of 
the Eye) study.56 The results of this seminal study provided 
the first definitive evidence of efficacy for a device allowing 
early detection and treatment of patients with neovascular 
AMD.57 The study compared the use of the ForeseeHome 
device plus standard care, compared with standard care alone, 
for eyes at high risk of progression to CNV, with visual 
acuity at the time of CNV detection taken as an indicator of 
early detection. The study was conducted in 44 clinical sites 
of AREDS2 (Age-Related Eye Disease Study 2), a clinical 
trial of nutritional supplements for the treatment of AMD. 
Study participants were at risk for developing CNV, with 
either bilateral large drusen or large drusen in one eye with 
advanced AMD in the fellow eye. Best-corrected visual acu-
ity of 20/60 or better was required in the study eye(s).
A total of 1,520 participants with a mean age of 72.5 years 
were enrolled.56,57 Those subjects randomized to the standard 
care-only arm received instructions that were investigator-
specific for self-monitoring of vision at home to detect 
progression of AMD (aids such as Amsler charts could be 
recommended). When participants experienced symptoms, 
they were instructed to call their clinical center immediately 
to schedule an appointment within 72 hours. In the other 
arm of the study, subjects received the home monitoring 
device, with instructions for installation and use, as well as 
standard care instructions. Participants were encouraged to 
use the device on a daily basis, and results were transmitted 
automatically via cellular modem to a central data-monitoring 
center. When the device testing suggested a change compared 
with the baseline measurements, an alert was sent from the 
monitoring center to the participant’s clinical center, prompt-
ing the staff to schedule a visit with the study ophthalmologist 
within 72 hours. The main outcome measure was the differ-
ence in best-corrected visual acuity scores between baseline 
and detection of CNV. Detection of CNV was determined 
by investigators based on clinical examination, color fundus 
photography, FA, and OCT findings.
A total of 763 participants were randomized to device 
monitoring, and 757 participants were randomized to standard 
care.56,57 Patients were followed up for a mean of 1.4 years 
between July 2010 and April 2013. At the prespecified 
interim analysis, 82 participants progressed to CNV: 51 in 
the device arm and 31 in the standard care arm. The primary 
analysis achieved statistical significance, with the participants 
in the device arm demonstrating a smaller decline in visual 
acuity with fewer letters lost from baseline to CNV detection 
(median  -4 letters, interquartile range -11.0 to -1.0 letters) 
compared with standard care (median -9 letters; interquartile 
range -14.0 to -4.0 letters) (P=0.021), resulting in better visual 
acuity at CNV detection in the device arm. With these convinc-
ing results, early termination of the study was recommended.
Use of preferential hyperacuity perimetry 
in retreatment regimens
PHP has also been suggested as a tool for monitoring the 
therapeutic response to PDT and anti-VEGF treatment in 
neovascular AMD. In a pilot study in 2011, Querques et al 
investigated the ability of Foresee PHP (ie, not the Foresee-
Home) in assessing responsiveness to ranibizumab therapy.58 
They examined 14 consecutive patients with newly diagnosed 
CNV secondary to AMD. These patients underwent PHP 
metamorphopsia testing before and shortly after treatment 
with ranibizumab. The mean PHP metamorphopsia test 
score improved significantly from 20.4635 at baseline to 
9.2623 after a single ranibizumab injection (P0.05). This 
improvement in metamorphopsia test scores correlated well 
with improvement in OCT parameters. In a follow-up study, 
the same authors investigated whether PHP metamorphopsia 
scores predicted the need for reinjection in patients receiv-
ing ranibizumab for neovascular AMD.59 They evaluated 
17 consecutive patients with newly diagnosed neovascular 
AMD being treated with ranibizumab over a 6-month period. 
At the third and sixth months, reevaluation for additional injec-
tions was done. PHP testing predicted the need for reinjection at 
each of these time points with an accuracy of 75% (sensitivity 
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83%±12%, specificity 67%±15%). From these results, the 
authors suggested that home testing with a PHP device 
(eg, ForeseeHome) might be effective to detect disease recur-
rences and thus guide optimal timing of retreatment decisions, 
with the potential for fewer unnecessary monitoring visits. This 
hypothesis has recently been investigated in a randomized clini-
cal trial (https://clinicaltrials.gov/ct2/show/NCT01336907).
Shape-discrimination hyperacuity
Basic principles
An alternative form of hyperacuity measurement involves the 
discrimination of shapes. Using radial frequency (RF) pat-
terns (perfect and distorted circular contours), Wilkinson et al 
demonstrated a very high sensitivity (ie, 10 seconds of arc) 
to sinusoidal deformation from circularity in test subjects.60 
This detection threshold was not affected by contrast reduc-
tion (contrast 10%) at low RFs, and showed little change 
with normal aging. It has been suggested that to achieve 
optimal performance, a global shape-detecting mechanism 
is involved, and therefore such a test may be particularly 
suitable for patients with AMD (a limitation of conventional 
visual acuity testing is that patients with macular disease can 
use a very small healthy foveolar area to achieve near-normal 
performance on visual acuity tests or on other types of testing 
that require only local processing).
In 2002, Wang et al confirmed that patients with AMD had 
significant deficits in performing global shape-discrimination 
tasks, both spatially and temporally.61 In each case, two RF 
patterns were presented, and test subjects were required to 
identify the deformed pattern. With spatial testing, 91% of 
eyes with AMD showed significant elevation of the thresh-
old for detecting radial deformation of RF patterns when 
compared with normal controls. With temporal testing, 97% 
of eyes with AMD showed significant threshold elevations. 
These shape-discrimination hyperacuity (SDH) deficits were 
present even though the subjects had good visual acuity 
(20/32) and contrast sensitivity (1.50 log units).
Handheld versus desktop testing 
protocols
A handheld SDH (hSDH) test (MyVisionTrack; Vital Art 
and Science, USA) has recently been implemented for use 
with smartphones. Such a device is of potential importance, 
as it may facilitate frequent, regular home monitoring for 
patients with AMD, and thus earlier detection and treat-
ment of CNV. In 2013, Wang et al reported the results of 
a study to 1) compare the hSDH testing protocol with an 
established desktop SDH testing protocol, 2) to compare 
hSDH with standard visual function measures, such as visual 
acuity and contrast sensitivity, and 3) to evaluate the effect 
of severity of maculopathy on hSDH.62 They evaluated 100 
subjects – 27 healthy volunteers, 37 patients with AMD, 
and 36 patients with DR – all with visual acuity 20/100. 
They found that handheld and desktop SDH testing were in 
agreement, and that measurements were higher in those with 
advanced AMD than in those with intermediate AMD. In an 
associated usability survey, test participants reported that the 
handheld testing was easy to use. As a result of this work, 
the MyVisionTrack application has recently been approved 
by the FDA for use by prescription only.
Health Management Tool
The Health Management Tool (HMT), a remote monitoring 
system that utilizes the MyVisionTrack app, has recently 
been tested in a pilot clinical trial.63 In the HMT system, 
patients use a handheld device daily to test their retinal 
visual function between clinic visits. Data input by patients 
is transferred in real time to a database, which sends remind-
ers to users regarding the test. Clinicians log in to the HMT 
database from an Internet-based dashboard to view results 
and compliance information (similar systems have been 
used previously for remote blood-pressure monitoring). 
This single-arm, prospective, open-label, 16-week, multi-
center pilot study was conducted at 24 centers in the US 
(NCT01542866). The primary objective of this study was to 
determine the sensitivity and specificity of MyVisionTrack 
to detect disease progression in patients with neovascular 
AMD receiving treatment with ranibizumab.
Patients with neovascular AMD in at least one eye and 
eligible for ranibizumab therapy were enrolled.63 Patients per-
formed SHD testing daily on the HMT device (iPhone 3GS, 
Apple) using the MyVisionTrack application. Data entered 
into HMT devices were collected in the HMT database, which 
also sent reminders for patients to perform testing. Among 
160 patients from 24 US centers enrolled in the study, 84.7% 
on average complied with daily MyVisionTrack testing and 
98.9% complied with at least weekly MyVisionTrack testing. 
The HMT database successfully uploaded more than 17,000 
MyVisionTrack assessment values and sent more than 9,000 
reminders. At the time of writing, the actual results of the 
trial have yet to be published.
Macular mapping test
Basic principles
The macular mapping test (MMT) is designed primarily 
for quick assessment of residual vision in patients with 
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maculopathies, but as it yields a quantitative score, it may 
also be used as a tool for monitoring disease progression.64,65 
The MMT is a software program used in conjunction with 
a desktop computer. Letters are briefly displayed in the 
central visual field (8° radius) on the computer display. A 
constant background pattern in a wagon-wheel shape aids 
the test subject in maintaining fixation at the center of the 
display area.
Clinical testing
In 2003, Trauzettel-Klosinski et al compared the results of 
MMT with those of manual kinetic perimetry in 50 patients 
with a variety of disorders that produce a central sco-
toma, including AMD, Stargardt’s disease, and diabetic 
maculopathy.66 They found little difference in the ability of 
the two tests to detect and delineate dense scotomas. In 2005, 
Bartlett et al investigated the test–retest variability of the 
MMT.67 Thirty-one healthy eyes of 31 normal subjects under-
went the test. MMT readings were also taken from 17 eyes of 
17 patients with soft drusen and 12 eyes of 12 patients 
with GA secondary to AMD. They concluded that despite 
considerable variability, the MMT score could be useful for 
monitoring progression of AMD.
Entoptic perimetry
Basic principles
The subjective perception of scotomas is often greatly 
reduced by the filling-in phenomenon (see earlier).31 In some 
instances, however, this phenomenon can be overcome by 
gazing at random visual noise, such as video static. When 
patients with an acquired scotoma stare at such a scene, 
they often perceive an inhomogeneous region correspond-
ing to their scotoma. Once the scotoma is perceived in this 
manner, it is often possible to map it, a procedure referred 
to as entoptic perimetry.64,65,68 Although this approach is 
not very effective in eliciting scotomas from postchiasmal 
lesions or from the physiological blind spot,69 variations 
of this technique have been successfully used to screen for 
visual field defects caused by prechiasmal ocular diseases, 
including AMD.
Clinical testing
In 2004, Freeman et al demonstrated the technique of 
scanning laser entoptic perimetry in patients with AMD.70 
In this study, the noise field was generated by a computer-
software program, and was delivered to the patient via a 
scanning laser virtual retinal display. Their device had an 
overall sensitivity of 82% and a specificity of 100% for the 
detection of AMD. The sensitivity for early stages of the 
disease is greater than 70%, and increases to above 90% for 
moderate-to-late stages.
Optical coherence tomography
Basic principles
OCT is a cross-sectional (tomographic) ocular imaging 
method, analogous to ultrasonography, but which measures 
reflected light waves rather than sound waves.71 In this tech-
nique, the combination of light reflected from a tissue of 
interest and light reflected from a reference path produces 
characteristic patterns of light interference dependent on the 
mismatch between the reflected waves. Since the time delay 
and amplitude of one of the waves is known, the time delay and 
intensity of light returning from the sample tissue may then 
be extracted from the interference pattern. As the wavelength 
of light is so much shorter than that of sound, OCT generates 
image sets with considerably superior resolution to those of 
ultrasonography (eg, typically 3–8 µm axial resolution in 
commercial systems).72,73
In the original OCT systems, the interference patterns 
generated were varied as a function of time using a mov-
ing mirror in the reference pathway; such devices were 
commonly referred to as “time-domain” OCT. Using time-
domain OCT, the AMD DOC study determined a greater 
specificity for OCT than Amsler chart or PHP testing in 
the detection of recent-onset CNV.74 However, a significant 
limitation of time-domain OCT devices is their slow image-
acquisition speed, which allows for only limited sampling 
of the macula in any given image set.75 As a result, it is not 
surprising that the AMD DOC study found a lower sensitivity 
of OCT imaging than FA for detection of CNV.74
In more recent OCT devices, the interference patterns 
generated are measured as a function of frequency, using 
a spectrometer.72 These “spectral domain” OCT devices 
remove the need for a moving reference mirror, and thus 
facilitate greatly enhanced image-acquisition speed. An alter-
native approach to the assessment of interference patterns in 
this way is through the use of a frequency-swept (“tunable”) 
laser light source: so-called swept-source OCT.
Handheld and binocular OCT
Swept-source OCT lasers are more robust and readily por-
table than spectral domain-based OCT systems. This has 
allowed the generation of the first prototype handheld OCT 
systems.76 Swept-source OCT systems employing vertical 
cavity surface-emission lasers have a greatly increased 
depth range compared to normal OCT systems (typically 
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20 times greater, or 40 mm versus approximately 2 mm).77,78 
The greatly increased range of imaging for these lasers also 
allows simultaneous capture of the anterior and posterior 
segments of the eye: so-called whole-eye OCT or OCT 
ophthalmoscopy.
The concept of binocular OCT has recently been 
described.79 In these systems, swept-source lasers are used to 
obtain simultaneous whole-eye images from each eye in tan-
dem. The binocular design of such a device removes the need 
for additional personnel to acquire the image by enabling 
patients to align the optical axes of the instrument with the 
optical axes of their own eyes. Binocular OCT systems can 
also offer advanced display, input, and computing capabilities 
relative to conventional OCT platforms. The internal screens 
on a binocular OCT device can function like applications 
on a smartphone, presenting content (eg, letters) to the user, 
and registering responses with voice-recognition software 
or external buttons. Using this approach, “smart” binocular 
OCT systems can accomplish the functions of many different 
diagnostic devices in a single instrument. Finally, binocular 
OCT systems allow image capture from both eyes at the 
same time. This “simultaneous” ocular imaging extends the 
range of functional testing possible, allowing for such fea-
tures as pupillometry and ocular motility. Through the rapid, 
automated acquisition of comprehensive ocular examination 
data, binocular OCT examination has the potential to transfer 
routine eye examinations outside the hospital setting, with 
comprehensive, automated assessment at distant locations, 
allowing patients with chronic, nonthreatening disease to 
visit the clinic less often, and those with recurrent disease to 
be detected at an earlier stage. In particular, binocular OCT 
may allow more frequent assessments in patients with AMD 
and potentially earlier detection of disease.
OCT angiography
An important focus of current OCT research is the generation 
of three-dimensional maps of the retinal and choroidal vascu-
lature: so-called OCT angiography.80 A number of techniques 
for OCT angiography are currently under development.81,82 In 
essence, these all involve high-speed, sequential acquisition 
of OCT A-scans or B-scans at the same retinal locus, and then 
assessment of differences in the scans that occur as a result 
of blood flow. After acquisition of OCT angiography image 
sets, it is possible to generate three-dimensional renderings 
of the vasculature or two dimensional fundic images with 
color coding for vessel depth. The development of nonin-
vasive OCT angiography may allow even earlier detection 
of CNV development than conventional OCT devices (eg, 
identification of the budding neovascular network prior to 
any exudation occurring that makes the diagnosis obvious 
with conventional OCT).
Conclusion
Ophthalmology is among the most technology-driven of 
all medical specialties. The advent of mobile-technology 
platforms, such as smartphones, tablet computers, and other 
devices, presents many unique opportunities to allow for 
earlier detection and treatment of patients with AMD. These 
changes are occurring in parallel with rapid evolution in the 
sophistication and utility of visual function testing; in par-
ticular, hyperacuity testing of particular efficacy in elderly 
populations with macular disease. The recent results of the 
Phase III HOME study provide robust evidence for the impor-
tance of these strategies.57 The challenge for retina specialists 
in the coming years will be to build on these advances in a 
usable, cost-effective, and widely available manner.
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